JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Add like
Add dislike
Add to saved papers

Effectiveness of prefabricated and customized foot orthoses made from low-cost foam for noncomplicated plantar fasciitis: a randomized controlled trial.

OBJECTIVES: To evaluate the effectiveness of prefabricated and customized foot orthoses made from low-cost foam (ethylene vinyl acetate [EVA]) in plantar fasciitis.

DESIGN: Double-blinded randomized controlled trial.

SETTING: Public rehabilitation referral medical center.

PARTICIPANTS: One hundred forty-two adults (75% women) with plantar fasciitis, without anatomical alterations in the feet. Seventeen subjects (12%) were lost during the follow-up.

INTERVENTIONS: Prefabricated and customized foot orthoses, both made from EVA, used for 8 weeks.

MAIN OUTCOME MEASURES: The primary outcome was pain (modified subscale of the Foot Function Index, [FFI] pain). The secondary outcomes were pain elicited by palpation in the medial calcaneal tuberosity and modified FFI total. Each participant was reviewed in the 4th and 8th weeks of follow-up.

RESULTS: One hundred twenty-five participants returned to at least 1 of the follow-up evaluations (63 in the prefabricated and 62 in the customized groups). There was a significant improvement in both groups (P<.05), but there was no difference of modified FFI pain between intragroup differences at 4 (4.03 points; 95% confidence interval [CI], -4.2 to 12.3) and 8 weeks (3.93 points; 95% CI, -4.6 to 12.5).

CONCLUSIONS: The low-cost prefabricated and customized foot orthoses, as used in this trial, had similar effectiveness in the treatment of noncomplicated plantar fasciitis after 8 weeks of use. Our results were similar to other trials, although those trials did not use orthoses made from EVA. Thus, EVA prefabricated inserts may be the best choice for the treatment of plantar fasciitis without complication.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app